Cronos Group (TSE:CRON) Trading 1.6% Higher – Time to Buy?

Cronos Group Inc. (TSE:CRONGet Free Report)’s stock price was up 1.6% during trading on Tuesday . The stock traded as high as C$3.85 and last traded at C$3.81. Approximately 88,037 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 177,427 shares. The stock had previously closed at C$3.75.

Analysts Set New Price Targets

Separately, TD increased their target price on shares of Cronos Group from C$4.50 to C$5.50 and gave the stock a “buy” rating in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Cronos Group currently has an average rating of “Buy” and a consensus target price of C$4.75.

Get Our Latest Stock Report on CRON

Cronos Group Stock Up 0.3%

The company has a market cap of C$1.45 billion, a P/E ratio of -188.00, a PEG ratio of 0.12 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a current ratio of 21.87 and a quick ratio of 24.01. The business’s 50 day moving average price is C$3.74 and its 200-day moving average price is C$3.67.

Cronos Group (TSE:CRONGet Free Report) last posted its quarterly earnings data on Monday, May 11th. The company reported C$0.06 EPS for the quarter. Cronos Group had a negative return on equity of 0.19% and a negative net margin of 1.29%.The company had revenue of C$62.86 million for the quarter. On average, analysts anticipate that Cronos Group Inc. will post -0.26 earnings per share for the current fiscal year.

Cronos Group Company Profile

(Get Free Report)

Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S.

Read More

Receive News & Ratings for Cronos Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cronos Group and related companies with MarketBeat.com's FREE daily email newsletter.